Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry;Charakteristika und Versorgung der idiopathischen Lungenfibrose: Rationale für das INSIGHTS-IPF-Register

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 49, 2012, Pages 2586-2588

  Behr, J ^a   Hoeper, M M ^b   Kreuter, M ^c   Klotsche, J ^d   Wirtz, H ^e   Pittrow, D ^f  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

clinical practice; management; observational study; patient related outcomes; resource utilization

Indexed keywords

ARTICLE; DISEASE MANAGEMENT; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; CROSS-CULTURAL COMPARISON; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PYRIDONES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; REGISTRIES; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84870052946     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1327244     Document Type: Article

References (28)

1. Brook R. H., McGlynn E. A., Cleary P. D. Measuring quality of care - part two of six. N Engl J Med: 1996; 335 966 970
2. Coultas D. B., Zumwalt R. E., Black W. C. et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med: 1994; 150 967 972
3. du Bois R. M. Idiopathic pulmonary fibrosis: present understanding and future options. Eur Respir Rev: 2011; 20 132 133
4. Eakin E. G., Resnikoff P. M., Prewitt L. M. et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest: 1998; 113 619 624
5. European Commission EurIPFnet European IPF Network: Natural course, Pathomechanisms and Novel Treatment Options in Idiopathic Pulmonary Fibrosis. Internet: http://ec.europa.eu/research/health/medical-research/ rare-diseases/projects/euripfnet-en.html Letzter Zugriff 12.03.2012
6. European Medicines Agency (EMA) Esbriet. CHMP Public Assessment Report EMA/CHMP/115147/2011. London 16 December 2010. http://www.ema.europa.eu/docs/en- GB/document-ibrary/EPAR-Public-assessment-report/human/002154/WC500103073.pdf Letzter Zugriff 22.10.2012
7. Gemeinsamer Bundesausschuss (G-BA) Zusammenfassende Dokumentation über die Änderung der Arzneimittelrichtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V: Pirfenidon. Berlin 15. März 2012. Internet: http://www.g-ba.de/downloads/40-268-1915/2012-03-15-AM-RL-XII- Pirfenidon-ZD.pdf Letzter Zugriff 22.10.2012
8. Glatz U. GOLDnet - seltene Lungenerkrankungen im Visier. Dtsch Med Wochenschr: 2011; 136 621
9. Gribbin J., Hubbard R. B., Le Jeune I. et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax: 2006; 61 980 985
10. Guenther A., Eickelberg O., Preissner K. T. et al. International registry for idiopathic pulmonary fibrosis. Thorax: 2008; 63 841 author reply 841
11. Iwai K., Mori T., Yamada N. et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med: 1994; 150 670 675
12. Kanematsu T., Kitaichi M., Nishimura K. et al. Clubbing of the fingers and smooth-muscle proliferation in fibrotic changes in the lung in patients with idiopathic pulmonary fibrosis. Chest: 1994; 105 339 342
13. Karakatsani A., Papakosta D., Rapti A. et al. Epidemiology of interstitial lung diseases in Greece. Respir Med: 2009; 103 1122 1129
14. Mura M., Porretta M. A., Bargagli E. et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis. Europ Resp J: 2012; 40 101 109
15. National Heart Lung and Blood Institute (NHLBI) Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful. (NIH News, 21. October 2011). http://www.nih.gov/news/health/ oct2011/nhlbi-21.htm Letzter Zugriff 22.10.2012
16. Noble P. W., Albera C., Bradford W. Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY). Lancet: 2011; 377 1760 1769
17. Ohshimo S., Bonella F., Cui A. et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2009; 179 1043 1047
18. Raghu G. Idiopathic pulmonary fibrosis. A rational clinical approach. Chest: 1987; 92 148 154
19. Raghu G., Collard H. R., Egan J. J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med: 2011; 183 788 824
20. Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2006; 174 810 816
21. Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med: 2011; 365 1079 1087
22. Scott J., Johnston I., Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ: 1990; 301 1015 1017
23. Selman M., Carrillo G., Estrada A. et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One: 2007; 2 e482
24. Song J. W., Hong S. B., Lim C. M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J: 2011; 37 356 363
25. Swigris J. J., Brown K. K., Behr J. et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med: 2010; 104 296 304
26. von Plessen C., Grinde O., Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med: 2003; 97 428 435
27. Wilson J. W., du Bois R. M., King T. E. Jr. Challenges in pulmonary fibrosis: 8 - The need for an international registry for idiopathic pulmonary fibrosis. Thorax: 2008; 63 285 287
28. World Health Organisation (WHO) http://www.cure4you.dk/354/index.php?m= 2&a=e2&ei=4151 Letzter Zugriff 22.10.2012